Argent BioPharma (ASX:RGT) executed a further deed of variation with a fund managed by US fund manager Mercer Street Capital Partners for its convertible securities agreement, according to a Wednesday filing with the Australian bourse.
The deed includes refinancing 300,000 convertible notes totaling AU$1.6 million, the filing stated. The companies also agreed to reduce the conversion price to no less than AU$0.30 from at least AU$10.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。